Anti-VEGF therapy appears to be an effective treatment for the retina; however, prolonged and/or frequent treatments may be associated with an increased risk of ocular local and/or systemic adverse events, including geographic atrophy [55], cerebrovascular disease, and death [56]. Here, VEGFA is linked to atrophic macular degeneration.